Status:
UNKNOWN
New Antiviral Drugs for Treatment of COVID-19
Lead Sponsor:
Mansoura University
Conditions:
COVID
Drug Effect
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
Background: In December 2019, SARS-CoV-2 was isolated on Vero E6 and Huh7 cell lines after an outbreak of pneumonia of unknown origin in Wuhan, Hubei Province, China. Since the basis for pathogenesis ...
Detailed Description
* Research Design and Methodologies: This search will focus on patients with COVID 19 infection this study is a prospective cohort study based on the analysis of response in comparative panel between...
Eligibility Criteria
Inclusion
- any subject with COVID-19 PCR positive pharyngeal swab and referred to the above-mentioned quarantine without any comorbidities and no sensitivity or contraindication to the three drugs.
Exclusion
- PATIENTS WITH COMORBIDITY :ISCHEMIC HEART DISEASES,OR KNOWN HYPERSENSITIVITY TO THE DRUGS
Key Trial Info
Start Date :
October 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04392427
Start Date
October 1 2020
End Date
May 1 2022
Last Update
September 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura University
Al Mansurah, Select A State Or Province, Egypt, 35516